Ortho Dermatologics announced the availability of Altreno (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients aged ≥9 years.
Altreno Lotion, a retinoid, also contains hyaluronic acid, glycerin, and collagen that act as moisturizers. It was approved in August 2018 based on results from 2 identical Phase 3 multicenter, randomized, double-blind, vehicle-controlled studies that showed Altreno Lotion resulted in statistically significant reductions in both inflammatory and non-inflammatory lesions vs vehicle. Dryness, pain, erythema, irritation, and exfoliation were the most common adverse reactions associated with Altreno Lotion.
“Altreno Lotion has demonstrated the efficacy of a tretinoin with a proven tolerability profile,” said Joshua Zeichner, MD, director, Cosmetic and Clinical Research in Dermatology, The Mount Sinai Hospital, New York City. “Greater tolerability may help improve adherence to skin care regimens, which may ultimately lead to better patient outcomes.”
Altreno Lotion should be used with caution in patients with known sensitivity or allergy to fish as the treatment contains soluble fish proteins.
Altreno is available as a 0.05% lotion in 45g tubes.
For more information call (800) 321-4576 or visit Altreno.com.
This article originally appeared on MPR